LRRK2: an éminence grise of Wnt-mediated neurogenesis? by Daniel C. Berwick & Kirsten Harvey
“fncel-07-00082” — 2013/5/30 — 12:41 — page 1 — #1
REVIEW ARTICLE
published: 31 May 2013
doi: 10.3389/fncel.2013.00082
LRRK2: an éminence grise of Wnt-mediated neurogenesis?
Daniel C. Berwick and Kirsten Harvey*
Department of Pharmacology, University College London School of Pharmacy, University College London, London, UK
Edited by:
Nelson Osses, Pontiﬁcia Universidad
Católica de Valparaíso, Chile
Reviewed by:
Fabio Blandini, C. Mondino National
Institute of Neurology Foundation,
Italy
Hermona Soreq, The Hebrew
University of Jerusalem, Israel
*Correspondence:
Kirsten Harvey, Department of
Pharmacology, University College
London School of Pharmacy,
University College London,
29-39 Brunswick Square,
London WC1N 1AX, UK
e-mail: kirsten.harvey@ucl.ac.uk
The importance of leucine-rich repeat kinase 2 (LRRK2) to mature neurons is
well-established, since mutations in PARK8, the gene encoding LRRK2, are the
most common known cause of Parkinson’s disease. Nonetheless, despite the LRRK2
knockout mouse having no overt neurodevelopmental defect, numerous lines of in vitro
data point toward a central role for this protein in neurogenesis. Roles for LRRK2 have
been described in many key processes, including neurite outgrowth and the regulation
of microtubule dynamics. Moreover, LRRK2 has been implicated in cell cycle control,
suggesting additional roles in neurogenesis that precede terminal differentiation. However,
we contend that the suggested function of LRRK2 as a scaffolding protein at the heart of
numerous Wnt signaling cascades provides the most tantalizing link to neurogenesis in
the developing brain. Numerous lines of evidence show a critical requirement for multiple
Wnt pathways in the development of certain brain regions, not least the dopaminergic
neurons of the ventral mid-brain. In conclusion, these observations indicate a function of
LRRK2 as a subtle yet critical mediator of the action ofWnt ligands on developing neurons.
We suggest that LRRK2 loss- or gain-of-function are likely modiﬁers of developmental
phenotypes seen in animal models of Wnt signaling deregulation, a hypothesis that can
be tested by cross-breeding relevant genetically modiﬁed experimental strains.
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LEUCINE-RICH REPEAT KINASE 2
Leucine-rich repeat kinase 2 (LRRK2) is a protein that has been
the subject of extensive research in recent years. This interest stems
from the identiﬁcation of LRRK2 as the product of the human
PARK8 gene, previously implicated as the cause of a familial form
of Parkinson’s disease in genetic linkage studies (Paisán-Ruíz et al.,
2004; Zimprich et al., 2004). Furthering interest in LRRK2, PARK8
has subsequently been associated with cancer, leprosy, and Crohn’s
disease (Hassin-Baer et al., 2009;VanLimbergen et al., 2009; Zhang
et al., 2009). The importance of LRRK2 to these diseases will not be
discussed further as the relevance to neuronal biology is limited.
Nonetheless, the association of a single gene with four distinct
medical conditions serves to highlight the complexity of LRRK2
function.
Parkinson’s disease is a currently incurable late-onset neurode-
generative disorder with increasing public health implications in
an aging population (Gasser, 2010). Therefore, uncovering the
molecular events causing this condition with the ultimate aim of
identifying therapeutic targets for diseasemodifying treatment has
gained in importance. The PARK genes mutated in patients with
familial Parkinson’s disease represent an obvious starting point
for this research. Although PARK8 is just one of more than a
dozen loci linked to Parkinson’s disease, certain lines of evidence
indicate that LRRK2 is of special relevance. Globally PARK8 muta-
tions are estimated to contribute to 1–5% of Parkinson’s disease
cases, which represents the greatest contribution from any known
genetic or environmental cause (Kumari and Tan, 2009). In some
populations, most notably North African Berbers, PARK8 muta-
tions are very common and account for as much as two-ﬁfths
of all Parkinson’s disease cases (Lesage et al., 2005; Jasinska-Myga
et al., 2010). Importantly, patients with PARK8 mutations exhibit
symptoms that are clinically indistinguishable from the more
common idiopathic form of Parkinson’s disease, while observed
post-mortem brain pathologies are also largely identical (Zim-
prich et al., 2004). Thus, it seems likely that LRRK2 also plays a
role in an as yet undeterminedprocess that is deregulated very early
in the pathogenesis of idiopathic Parkinson’s disease (Kumari and
Tan, 2009; Berwick and Harvey, 2011).
From a biochemical perspective, there are two immediate
observations to be made about LRRK2. First, LRRK2 is a large
(2527 amino acid) protein, containing multiple protein–protein
interaction domains (Figure 1). Unsurprisingly, a vast number
of interaction partners have been reported and LRRK2 has been
suggested to function primarily as scaffolding protein (Berwick
and Harvey, 2011; Lewis and Manzoni, 2012). Indeed, the breadth
of reported interactors is so wide that LRRK2 probably functions
in a number of distinct multi-protein complexes. Second, LRRK2
contains two separate enzymatic activities: serine–threonine phos-
phorylation (kinase activity) and guanine triphosphate hydrolysis
(GTPase activity). Understandably, this has lead to the sugges-
tion of alternative roles for LRRK2 as a “conventional” signaling
protein, either functioning as a protein kinase or in an analogous
manner to small GTPases such as Ras or Rac (Berwick and Harvey,
2011).
A detailed review of LRRK2 function is beyond the scope of
this article, but what is most important to stress is that the func-
tion of LRRK2 remains unclear and in many cases is controversial.
For example, 8 years of research have failed to ﬁnd a reproducible
kinase substrate other than LRRK2 itself, while there is still no
agreement on whether the GTPase activity controls kinase activity
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FIGURE 1 | Domain structure of LRRK2. Domains are color-coded according
to function: those implicated in protein–protein interaction are depicted in
blue; domains involved in GTPase function are green; and the kinase domain
red. Here, LRRK2 is depicted as a dimer, although LRRK2 also exists as
monomers and in higher molecular weight complexes (Greggio et al., 2008).
Dimerization is likely to be mediated by the COR and/orWD40 domains
(double-headed arrows). COR domains are established as dimerization
devices in ROCO proteins (Gotthardt et al., 2008), whilst ablation of theWD40
domain has been reported to disrupt LRRK2 dimerization (Jorgensen et al.,
2009). The location of pathological mutations proven to segregate with
Parkinson’s disease are shown with asterisks and bold font. Although only
considered a risk factor, the G2385R mutation is also depicted with a plus
sign, since this mutation is mentioned in the main text and is very frequent
amongst Asian populations. ARM, armadillo repeat; ANK, ankyrin repeat;
LRR, leucine-rich repeat; Roc, ras of complex proteins; COR, c-terminal of
Roc; Kin, kinase.
or vice versa. It seems probable therefore that these functions are
interdependent. In any case, the enzymatic activities of LRRK2 are
certainly of some importance in the physiological and pathological
function of this protein. To date all described PARK8 mutations
clearly segregating with Parkinson’s disease cause changes in the
GTPase or kinase domains, but not in any of the protein–protein
interaction domains (Figure 1). Over-expression of LRRK2 in
cultured cells and transgenic animals has been widely reported
to cause cytotoxicity (Greggio et al., 2006; Smith et al., 2006; Iac-
carino et al., 2007; West et al., 2007; Xiong et al., 2010; Stafa et al.,
2012; Biosa et al., 2013). Whether this observation reﬂects an
artifactual effect of over-expressing this large protein is unclear.
Nonetheless, it is now generally accepted that this observed cyto-
toxicity is enhanced by PARK8 mutations but ameliorated by loss
of LRRK2 kinase or GTPase activity. In light of this, much work
has been predicated on the idea that pathological effects of PARK8
mutations require LRRK2 kinase activity, and in consequence a
great deal of effort has gone into developing a pharmacological
inhibitor of LRRK2 kinase activity (Ray and Liu, 2012). However,
although the common G2019S mutation has been reproducibly
shown to elicit increased LRRK2 kinase activity this mutation
appears unique: all other mutations segregating with Parkinson’s
disease have no reproducible effect on kinase activity (Greggio and
Cookson, 2009). Furthermore, the G2385R mutation, a risk fac-
tor within Asian populations, has been reported to have decreased
kinase activity (Rudenko et al., 2012). Thus LRRK2 kinase activ-
ity appears to regulate the function of this protein, but whether
increased kinase activity is responsible for pathogenesis in PARK8
patients remains to be established. In conclusion, we favor a model
where LRRK2 functions primarily as a scaffold that nucleates mul-
tiple protein complexes, but where protein function is nonetheless
dependent on LRRK2 kinase and GTPase activities.
Despite considerable disagreement about LRRK2 function at
the biochemical level, cell biological and transgenic animal stud-
ies have allowed advances to be made. In the following section
we review aspects of LRRK2 biology where there are sufﬁcient
data to paint an overall picture that is beyond dispute, even if
speciﬁc details are controversial or not yet known. We value the
importance of work performed in lower organisms and will men-
tion data obtained from these systems where pertinent, however,
this review will focus on mammalian data. This distinction is jus-
tiﬁed since mammals express two LRRK proteins, LRRK1 and
LRRK2, which despite strong similarities in sequence and struc-
ture appear to have contrasting functions. Lower organisms, in
particular Drosophila melanogaster and Caenorhabditis elegans,
encode a single LRRK protein, which is thus the ortholog of
both LRRK1 and LRRK2. As we outline, there is sufﬁcient evi-
dence in existence to make roles for LRRK2 in three processes
that underlie neurogenesis beyond debate. These are roles in
synaptic and endosomal vesicle trafﬁcking, macroautophagy, and
regulation of microtubule dynamics are illustrated in Figure 2.
Furthermore, an effect of LRRK2 on neurite outgrowth – a direct
measure of the latter stages of neurogenesis – is extremely well
supported. Coupled with growing evidence of roles in adult neu-
rogenesis and in proliferation we contend that these data make
a strong case for a central role for LRRK2 in multiple stages of
neurogenesis.
ROLES FOR LRRK2 IN FUNCTIONS UNDERLYING
NEUROGENESIS
Regulated membrane trafﬁcking events underlie many key
processes involved in neurogenesis. These include requirements
for endocytosis for the proper function of neurogenic signal-
ing pathways, such as Notch and Wnt cascades, and membrane
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FIGURE 2 | LRRK2 regulates cell biological functions important for
neurogenesis. Several lines of evidence support roles for LRRK2 in
microtubule function, endocytosis/vesicle trafﬁcking and autophagy. LRRK2 is
likely to impact upon neurite outgrowth and the latter stages of neurogenesis
through direct association with membrane structures and microtubules and/or
regulation of signaling pathways. In addition, LRRK2 has been implicated in
proliferation and may therefore also govern early stages of neurogenesis. The
interaction between microtubule function, vesicle trafﬁcking, autophagy and
proliferation and the canonical Wnt pathway is depicted but other pathways
are likely to play additional roles.
receptors involved in axonal outgrowth (Blitzer and Nusse, 2006;
Le Borgne, 2006; Winckler and Yap, 2011). Importantly, roles for
LRRK2 in membrane trafﬁcking events are supported by data
extending from early reports placing LRRK2 protein on cellular
membranes (Biskup et al., 2006; Hatano et al., 2007) to evidence
of vacuolation in LRRK2 knockout mouse kidney cells (Tong
et al., 2012). Intriguingly, the kinase activity of LRRK2 appears
to be enhanced at membranes (Berger et al., 2010), while the dis-
tribution of LRRK2 between membrane and cytosolic fractions
can be regulated by extracellular stimuli (Berwick and Harvey,
2012a). These observations suggest that LRRK2 plays an active
role in membrane trafﬁcking events, and is not simply present as
a by-stander.
The precise membranous compartments and/or vesicles
LRRK2 inhabits remains contentious since many have been
suggested, however, membrane compartments involved in two
cellular processes – pre-synaptic vesicle trafﬁcking and macroau-
tophagy – stand prominent. Evidence of a role for LRRK2 in the
trafﬁcking of pre-synaptic vesicles comes from multiple experi-
mental techniques. These include localization of LRRK2 to vesicles
in synaptic terminals by confocal and electron microscopy (Xiong
et al., 2010; Piccoli et al., 2011), demonstrable electrophysiologi-
cal defects following knock-down or over-expression of LRRK2
in cultured neurons (Shin et al., 2008; Piccoli et al., 2011), and
biochemical interaction and co-localization of LRRK2 with the
early endosomal marker Rab5b (Shin et al., 2008). The function
of LRRK2 in pre-synaptic vesicular compartments remains to be
determined, although a recent report that the LRRK2 homolog
in Drosophila phosphorylates endophilin A proteins is promising
(Matta et al., 2012).
A wealth of data implicate LRRK2 in macroautophagy, the
process by which damaged organelles and protein aggregates
are “consumed” by engulfment by membranous autophagosomes
that subsequently fuse with lysosomes (Codogno et al., 2012).
Macroautophagy is traditionally considered a mechanism of cel-
lular homeostasis and regulated cell death. However, neural
development is especially dependent on this process, most likely
for mediating the extensive physical remodeling required (Cec-
coni et al., 2007; Cecconi and Levine, 2008). Studies performed
using mouse models of LRRK2 dysfunction have been particularly
revealing, since multiple observations show impaired macroau-
tophagy in the kidney of Lrrk2 null animals (Tong et al., 2010,
2012; Herzig et al., 2011). These data include increased num-
bers of lysosomes and related structures, and an accumulation
of the macroautophagy substrates p62 protein and lipofuscin
granules. Much of this kidney phenotype appears to be repli-
cated in transgenic mice that over-express LRRK2 containing an
artiﬁcial kinase-inactivating mutation (Herzig et al., 2011). In
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agreement with these observations, over-expression of LRRK2
impacts upon the autophagic pathway in human embryonic kid-
ney 293 (HEK293) cells (Alegre-Abarrategui et al., 2009; Gómez-
Suaga et al., 2012). Importantly, published data also support a role
for LRRK2 in macroautophagic processes in the central nervous
system. Most notably, brains from aged transgenic mice that over-
express human LRRK2 variants containing either the R1441C or
G2019S PARK8 mutations have an accumulation of autophagic
vacuoles (Ramonet et al., 2011). This observation appears to be
corroborated in vitro, where over-expression of G2019S has simi-
lar effects in cultured primary neurons or differentiated SH-SY5Y
cells (MacLeod et al., 2006; Plowey et al., 2008).
Studies in Drosophila suggest another connection between
LRRK2 and macroautophagy: via interaction with the small
GTPase Rab7 (Dodson et al., 2012). Rab7 is well-established as
a key regulator of the fusion step between macroautophagic
organelles and lysosomes (Codogno et al., 2012). If this obser-
vation can be replicated in mammalian systems it would be a
fascinating result, since Rab7 is also involved in the latter stages
of endocytosis, mediating late endosomal maturation and fusion
with the lysosome (Wang et al.,2011). Asmentioned above, LRRK2
has also been reported to interact with Rab5b (Shin et al., 2008).
Since Rab5 proteins link pre-synaptic vesicle trafﬁcking with early
stages of endocytosis and Rab7 links autophagy with late-stage
endocytosis, these observations together connect LRRK2 with the
entire endocytic pathway.
In neurons endocytic vesicles can be trafﬁcked over huge dis-
tances, particularly in axons. The importance of microtubules for
this process is well described (Perlson et al., 2010). It is therefore
interesting that an association between LRRK2 and microtubules
has been reported by a large number of groups (Biskup et al., 2006;
Gloeckner et al., 2006; Gandhi et al., 2008; Gillardon, 2009a,b; San-
cho et al., 2009; Dzamko et al., 2010; Kawakami et al., 2012; Kett
et al., 2012; Sheng et al., 2012). This physical association appears
highly relevant to neurogenesis as LRRK2 has been reported to
co-localize with microtubules within growth cones (Sancho et al.,
2009).
The nature of the LRRK2-microtubule interaction is still unre-
solved. For example, there are conﬂicting reports about whether
inhibition of LRRK2 kinase activity promotes (Dzamko et al.,
2010) or weakens (Kett et al., 2012) the association. However, a
role for LRRK2 in microtubule dynamics seems beyond dispute.
Certain clues suggest LRRK2 may affect the stability of micro-
tubules. LRRK2 has been reported to enhance the polymerization
of bovine tubulin in the presence of microtubule-associated pro-
teins (MAPs) in vitro (Gillardon, 2009b). In addition, LRRK2 has
been linked to canonical Wnt signaling (Sancho et al., 2009; Lin
et al., 2010; Berwick and Harvey, 2012a), which is well described
as a modulator of the microtubule cytoskeleton in neurons (Sali-
nas, 2007). Perhaps most strikingly though, numerous lines of
in vivo data implicate LRRK2 in modulating the function of the
MAP tau, best known for its role in Alzheimer’s disease (Tay-
mans and Cookson, 2010). Post-mortem analysis of Parkinson’s
disease brains carrying Y1699C, G2019S, or I2020T PARK8 muta-
tions have been reported to display “tau pathology” in a number
of cases (Zimprich et al., 2004; Khan et al., 2005; Rajput et al.,
2006; Ujiie et al., 2012). Tau hyperphosphorylation has also been
reported in brains from transgenic mice over-expressing LRRK2
with the G2019S or R1441G mutations (Li et al., 2009; Melrose
et al., 2010), while Lrrk2 knockout has been reported to decrease
tau phosphorylation (Gillardon,2009b) althoughothers have been
unable to replicate this observation (Hinkle et al., 2012). G2019S
LRRK2 has also been reported to promote tau phosphorylation
in Drosophila (Lin et al., 2010). Mechanistically, the details linking
LRRK2 to tau phosphorylation are lacking but one might predict
the interaction between LRRK2 and microtubules would bring
LRRK2and tau intoproximity. Indeed, a recent report suggests this
may be the case (Kawakami et al., 2012). Whether LRRK2 phos-
phorylates tau directly remains unclear with one study supporting
direct phosphorylation (Kawakami et al., 2012), and another sug-
gesting that phosphorylation is performed by glycogen synthase
kinase 3 (GSK3; Lin et al., 2010), a reported LRRK2 interactor
(Lin et al., 2010; Berwick and Harvey, 2012a). These reports are
not necessarily in conﬂict, since the experimental systems used are
different and tau contains over 80 reported phosphorylation sites
(http://cnr.iop.kcl.ac.uk/hangerlab/tautable). However, the pos-
sibility that phosphorylation is via GSK3 is intriguing, since this
kinase has been implicated in the control of multipleMAPs besides
tau, such as adenomatous polyposis coli (APC;Zhouet al., 2004) and
collapsin response mediator protein 2 (Cole et al., 2004). There-
fore, it is plausible that the control of microtubule dynamics by
LRRK2 involves the modulation of a multitude of MAPs and takes
place at a variety of microtubule sites, not just those regulated by
tau in axons.
Parallel to a role for LRRK2 on microtubules, LRRK2 has
also been connected to the actin cytoskeleton via the regula-
tion of ERM (ezrin–radixin–moesin) protein phosphorylation.
ERM proteins are three homologous proteins involved in anchor-
ing actin ﬁlaments to the plasma membrane (Mangeat et al.,
1999). Phosphorylation of ERM proteins is believed to induce
a conformational change resulting in an open “active” shape
(Mangeat et al., 1999). Two groups have found a positive corre-
lation between LRRK2 levels and ERM protein phosphorylation
(Jaleel et al., 2007; Parisiadou et al., 2009), that is most likely
mediated by an indirect regulation (Nichols et al., 2009). Impor-
tantly, ERM proteins are essential for growth cone morphology
and motility (Paglini et al., 1998), thus indicating that LRRK2 also
impacts upon neurogenesis through ERM proteins. The connec-
tion between LRRK2 and the actin cytoskeleton is strengthened
by a mass spectrometry study which found endogenous LRRK2
in HEK293 cells to associate with actin and a number of proteins
known to modulate the actin cytoskeleton (Meixner et al., 2011).
In light of these observations, it is interesting to speculate about
a role for LRRK2 in coordinating neuronal microtubule as well as
actin networks.
Thus, there are several lines of evidence for the importance of
LRRK2 in a number of processes that underlie neurogenesis, but
what evidence directly supports a requirement for LRRK2 in neu-
rogenesis? Importantly, a comprehensive study in mouse embryos
found a spatio-temporal LRRK2 mRNA expression pattern that
is highly consistent with a key role for LRRK2 in neurogenesis
(Zechel et al., 2010). Using in situ hybridization, LRRK2 mRNA
expression was detected as early as day E10.5 in the developing
central nervous system, with transcript detectable throughout the
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cortex by day E12.5. Crucially, the authors describe embryonic
expression of Lrrk2 as being most prominent in brain regions
with “high proliferative and migratory activity, as well as sites of
differentiation and cell death” (Zechel et al., 2010). These include
the ventricular and subventricular zones of the telencephalon, in
agreement with a previous report investigating older mice (Mel-
rose et al., 2007). Lrrk2 was also found to be expressed in neural
stem cells isolated from the dentate gyrus or striatal subventricular
zone of E18.5 or adult mice. Thus LRRK2 expression patterns are
consistent with a role in neurogenesis throughout life.
It is thus unsurprising that a growing body of experimental data
show defects in neurogenesis caused by altered LRRK2 function.
Experiments in cell and animal models utilized LRRK2 knock-
down or knockout, over-expression of wild-type LRRK2, familial
LRRK2 mutants and artiﬁcial kinase or GTPase dead mutants to
measure predominantly neurite outgrowth and reported changes
in length, number and branching of neurites in vitro and in brain
slices. Most reports agree that the over-expression of familial
LRRK2 mutants elicit decreased neurite length (MacLeod et al.,
2006; Plowey et al., 2008; Parisiadou et al., 2009; Dächsel et al.,
2010; Heo et al., 2010; Lin et al., 2010; Chan et al., 2011; Ramonet
et al., 2011; Winner et al., 2011; Maekawa et al., 2012; Sheng et al.,
2012; Stafa et al., 2012; Biosa et al., 2013; Cherra et al., 2013; Cho
et al., 2013). Over-expression of wild-type LRRK2 was generally
found to have no effect, or to cause mild neurite shortening, either
reaching statistical signiﬁcance or remaining as a trend. In con-
trast, loss of LRRK2 appears to have the opposite effect, allowing
longer and more branched neurites to develop (MacLeod et al.,
2006; Parisiadou et al., 2009; Dächsel et al., 2010; Heo et al., 2010;
Stafa et al., 2012; Paus et al., 2013), although not all studies are
in agreement (Gillardon, 2009b; Meixner et al., 2011). In gen-
eral, these studies provide overwhelming evidence that the level of
LRRK2 expression impacts upon neuritogenesis as predicted from
the LRRK2 expression pattern throughout brain development.
Finally, we also note two publications investigating a role for
LRRK2 in adult neurogenesis (Winner et al., 2011; Paus et al.,
2013). These studies are of special relevance to Parkinson’s dis-
ease,where impaired adult neurogenesis has been implicated in the
development of non-motor symptoms (Marxreiter et al., 2013). A
study inmice over-expressing theG2019S LRRK2mutant reported
decreased proliferation in the dentate gyrus and subventricular
zones associated with decreased dendritic length and branching,
and decreased cell survival (Winner et al., 2011). Another study
by Paus et al. (2013) looked at adult neurogenesis in the dentate
gyrus of Lrrk2 knockout mice. As might be predicted, increased
dendritic length andneurite arborizationwas observed. Nodefects
in cell proliferation or survival were found however, although loss
of Lrrk2 led to a greater number of doublecortin positive cells
(Paus et al., 2013).
Thus awealth of data implicates LRRK2 as a central player in the
latter stages of neurogenesis – in particular neurite outgrowth and
synaptogenesis – possibly via a combination of modulating vesicle
trafﬁcking and cytoskeleton dynamics. Nonetheless, emerging evi-
dence also links LRRK2 to earlier stages of neuronal development,
prior to cell cycle exit (Winner et al., 2011), supported by evidence
of effects of LRRK2 on proliferation (Milosevic et al., 2009; Liu
et al., 2012) and carcinogenesis (Hassin-Baer et al., 2009). Thus,
LRRK2might play a role from earlymitotic neuronal precursors to
terminal differentiation. As outlined above, we would suggest that
LRRK2 is likely to function as a scaffolding protein in a number
of distinct complexes, some of these important in neurogenesis.
Nonetheless, two crucial questions remain: what is upstream of
these complexes, and how are they regulated?
A ROLE FOR LRRK2 IN Wnt SIGNALING
Wnt (wingless/Int) signaling pathways constitute a family of highly
conserved signal transduction cascades that have long been estab-
lished as master regulators of animal development (Freese et al.,
2010). The relevance of these pathways to neurogenesis is beyond
doubt and will not be reviewed in detail in this article. Nonethe-
less the reader should be aware that a growing body of data also
implicates Wnt signaling in the function of mature, post-mitotic
neurons (Inestrosa andArenas, 2010). Moreover, deregulatedWnt
signaling pathways are suggested pathomechanisms for a number
of neurological conditions, including Alzheimer’s disease, Parkin-
son’s disease, autism, and schizophrenia (De Ferrari and Moon,
2006; Inestrosa and Toledo, 2008; Berwick and Harvey, 2012b).
Thus Wnt cascades can be considered essential for the central
nervous system at all stages of life.
Wnt ligands themselves are secreted glycoproteins that bind
to the extracellular domains of frizzled receptors on the plasma
membrane of target cells. Signaling speciﬁcity is achieved in part
through the large repertoire of Wnt ligands and frizzled receptors
expressed in higher organisms, but also through the involve-
ment of co-receptors. In the case of the canonical Wnt pathway,
these receptors are low-density lipoprotein receptor-like proteins
5 and 6 (LRP5/6), which have also been reported to bind Wnt
ligands at the cell surface. Upon binding of Wnt ligands to friz-
zled receptors and associated co-receptors the signal is relayed
across the membrane, resulting in the activation of one or more
intracellular cascades. Wnt signaling pathways relevant to neu-
rogenesis and/or the function of mature neurons are depicted in
Figure 3.
The best-described Wnt signaling cascade is the canonical Wnt
pathway. This signaling mechanism ultimately results in the acti-
vation and nuclear recruitment of β-catenin protein, leading to
the modulation of downstream target genes. In consequence, this
pathway is sometimes referred to as the Wnt-β-catenin pathway.
Canonical Wnt signaling is an unusual signaling mechanism as
several events take place in the absence of a stimulus. In particu-
lar, β-catenin is sequestered into an inhibitory cytosolic complex
known as the β-catenin destruction complex. Here, β-catenin
is phosphorylated by GSK3 (the same protein implicated in tau
phosphorylation). β-catenin phosphorylation results in the tar-
geting of β-catenin for degradation by the proteasome. Therefore,
in the absence of canonical Wnt pathway activators, β-catenin
is continually degraded, and consequently unable to accumulate
in the nucleus to regulate gene expression. Binding of Wnt lig-
and to frizzled receptors and LRP5/6 results in the recruitment of
cytosolic dishevelled (DVL) proteins (key intermediates of most
Wnt signaling branches) to the plasma membrane. Via interac-
tion with key components of the β-catenin destruction complex
such as Axin, DVL proteins cause the subsequent relocalization
of the β-catenin destruction complex to the same juxtamembrane
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FIGURE 3 | Overview ofWnt signaling pathways.The three
major branches ofWnt signaling – (A) the canonical, (B) planar cell
polarity (PCP), (C) andWnt-Ca2+ – pathways are illustrated. Note that
in growing neurites a further branch has been reported, the so-called
divergent canonical pathway, which impacts upon microtubule stability.
APC, adenomatous polyposis coli; CaN, calcineurin; CK1, casein kinase 1;
DAAM, dishevelled-associated activator of morphogenesis; DVL,
dishevelled; FzR, frizzled receptor; GSK3, glycogen synthase kinase 3;
JNK, c-Jun n-terminal kinase; LRP5/6, low-density lipoprotein
receptor-related protein 5/6; NFAT, nuclear factor of activatedT cells; PKC,
protein kinase C; PLC, phospholipase C; ROCK, Rho-associated protein
kinase.
site. This elicits the penultimate stage of canonical Wnt signal-
ing, the inhibition of β-catenin phosphorylation, which allows
β-catenin to become proteasome resistant and thus accumulate
throughout the cell. However, the complexity of this mecha-
nism is emerging. A requirement for the internalization of the
cell membrane-associated protein complex containing Wnt lig-
and, frizzled receptor, LRP5/6, DVL proteins, and the β-catenin
destruction complex into the endosomal system is now widely
accepted. This internalized signaling complex passes through the
endosomal system where it continues to signal from the cytoso-
lic face of intracellular membranes (the so-called “signalosome”
hypothesis). Finally, the signalosomes are sequestered from the
cytosol into multi-vesicular bodies. Traditionally, by analogy to
growth factor signaling pathways, this has been considered the
termination step in Wnt signaling. However, recent data suggest
that the sequestration of signalosomes into multi-vesicular bodies
constitutes a ﬁnal “signal activation” mechanism, since this leads
to the removal of the canonical Wnt signaling pool of GSK3 from
the cytosol (Dobrowolski and De Robertis, 2012).
Data from our laboratory has strongly implicated LRRK2 in
multiple aspects of the canonical Wnt pathway. This work arose
from a yeast two-hybrid screen identifying interactors of the
Roc and/or COR domains of LRRK2 (Sancho et al., 2009). Since
Roc and COR domains are expressed together throughout nature
(Marín et al., 2008), it is reasonable to consider both domains
part of a single functional unit conferring GTPase activity that
was termed the RocCOR tandem domain. Using this LRRK2 Roc-
COR tandem domain as bait, the yeast two-hybrid screen returned
cDNAs encoding the human DVL proteins DVL2 and DVL3 as
potential interactors. Subsequent assays conﬁrmed a direct inter-
action between the LRRK2 RocCOR domain and all three human
DVL proteins, with the interaction site mapped to the DVL–
Egl10–pleckstrin (DEP) domain of DVL1–3 (Sancho et al., 2009).
Co-immunoprecipitation experiments conﬁrmed that LRRK2
associates with DVL proteins in mammalian cells, while confocal
microscopy revealed a striking recruitment of LRRK2 into poly-
meric DVL structures that are induced by over-expression of these
proteins (Sancho et al., 2009).
Since DVL proteins are essential intermediates of all major
branches of Wnt signaling (Figure 3), our work opened the
possibility that LRRK2 may function in multiple Wnt cascades.
However, follow-up studies focused on the canonical Wnt path-
way, which can be assayed easily using TOPﬂash assays (Veeman
et al., 2003). TOPﬂash assays are luciferase-based reporter assays
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that quantitatively determine the level of β-catenin-mediated tran-
scriptional activity in cells. Importantly, TOPﬂash assays revealed
the LRRK2–DVL protein interaction to be functional as well as
physical, since co-transfection of LRRK2 protein with any of the
three human DVL proteins resulted in an enhancement of DVL-
driven canonical Wnt activity (Berwick and Harvey, 2012a). This
effect required the kinase and GTPase activities of LRRK2 and was
increased further by targeting LRRK2 (and presumably, there-
fore, the LRRK2–DVL interaction) to membranes. Interestingly,
Wnt3a treatment was found to increase the amount of endoge-
nous LRRK2 present in membrane fractions of HEK293 cells
(Berwick and Harvey, 2012a). Since the activation of canonical
Wnt signaling takes place at intracellular membranes – consis-
tent with the signalosome hypothesis – this lead us to investigate
whether LRRK2 might physically interact with Wnt signaling
receptors. Using a combination of confocal microscopy and co-
immunoprecipitation LRRK2 was discovered to associate with
LRP6, but not frizzled-1, frizzled-4, or frizzled-5. Yeast two-
hybrid assays conﬁrmed that the interactionwas direct and, similar
to interaction with DVL proteins, involved the LRRK2 RocCOR
tandem domain (Berwick and Harvey, 2012a). These data are con-
sistent with a role for LRRK2 in the activation of canonical Wnt
signaling bringing DVL proteins to cellular membranes.
However, somewhat counter-intuitively, knock-down of
LRRK2 was also found to potentiate DVL-driven TOPﬂash activ-
ity (Berwick and Harvey, 2012a). A similar effect was observed
on basal and Wnt3a-driven β-catenin activity. In this regard
knock-down of LRRK2 mimicked knock-down of AXIN1, an
established component of the β-catenin destruction complex. Loss
of AXIN1 is well-known to disrupt the β-catenin destruction com-
plex thereby compromising β-catenin degradation and leading to
an increase in basal canonical Wnt activity. We therefore won-
deredwhether loss of LRRK2might compromise an inhibitory role
for LRRK2 in the β-catenin destruction complex. Consistent with
this, co-immunoprecipitation of endogenous protein from mouse
brain revealed Lrrk2 to exist in complex with multiple compo-
nents of the β-catenin destruction complex, including GSK3 and
β-catenin. Taken together, these results suggest a role for LRRK2
as a scaffold in canonical Wnt signaling. In the basal state, LRRK2
functions as part of the cytosolic β-catenin destruction complex
and loss of LRRK2 compromises this role, leading to disruption
of the complex and pathway activation. Following stimulation of
cells with Wnt ligand, LRRK2 is recruited to cellular membranes.
Here, via interaction with DVL proteins, the β-catenin destruc-
tion complex and LRP6, LRRK2 assists in the formation of Wnt
signalosomes, enhancing the Wnt signal activity.
Our data are supported by work from other laboratories. Most
notably, supporting the idea that LRRK2 associates with the β-
catenin destruction complex, an interaction between LRRK2 and
GSK3 has been reported in Drosophila (Lin et al., 2010). While
this report does not investigate which cellular GSK3 pool asso-
ciates with LRRK2 we note that the interaction modulated tau
phosphorylation. Since Wnt signaling is well-known to regulate
the phosphorylation of tau by GSK3 (Hooper et al., 2008), this
would suggest that theGSK3pool found to bind LRRK2by Lin and
colleagues could indeed represent the same Wnt-responsive frac-
tion identiﬁed in our study (Lin et al., 2010; Berwick and Harvey,
2012a). Perhaps most interesting in this report, the LRRK2–GSK3
interaction was shown to be enhanced by the G2019S PARK8
mutation (Lin et al., 2010). Curiously, the strength of the LRRK2
interaction with both DVL proteins and LRP6 was also affected
by PARK8 mutations (Sancho et al., 2009; Berwick and Harvey,
2012a). Unsurprisingly therefore, all investigated PARK8 muta-
tions decreased the capacity of LRRK2 to enhance the β-catenin
activation elicited by DVL proteins (Berwick and Harvey, 2012a).
This observation has obvious implications for the pathogenesis
of Parkinson’s disease, where perturbed Wnt signaling has already
been suggested as a candidate pathomechanism (Berwick andHar-
vey, 2012b). However, as we outline below, decreased canonical
Wnt signaling associated with familial PARK8 mutations suggests
that transgenic LRRK2 animalmodels of Parkinson’s diseasemight
present with discrete developmental phenotypes associated with
Wnt dysfunction.
In addition to studies linking LRRK2 to Wnt signaling by
protein–protein interaction strong circumstantial evidence from
transcriptomics studies support this notion. In particular, an
investigation into the effect of LRRK2 knock-down in human
SH-SY5Y cells found mRNA species encoding a number of
Wnt signaling proteins to be altered (Häbig et al., 2008). As
it is well described that many Wnt signaling components are
regulated at the transcriptional level by pathway activation,
knock-down of LRRK2 would be expected to alter expression
of other Wnt signaling proteins. Data from C. elegans also sup-
port this observation, with mRNA transcripts encoding Wnt
signaling proteins being described as “coregulated with LRRK2”
(Ferree et al., 2012).
Further support, albeit indirect, of a role for LRRK2 in Wnt
signaling comes from studies investigating altered gene expres-
sion in animal models of Parkinson’s disease. These investigations
used a variety of different neurotoxins to elicit dopaminer-
gic cell death resulting in parkinsonian-like motor phenotypes.
L’Episcopo et al. (2011) reported increased Wnt1 gene expression
as well as deregulated Fzd1 and β-catenin expression in the ven-
tral mid-brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP)-treated mice. These experiments support the idea that
canonical Wnt signal activation via increased Wnt1 expression
in astrocytes is neuroprotective (L’Episcopo et al., 2011). Another
study used 6-hydroxydopamine (6-OHDA) to induce dopaminer-
gic cell death in rats resulting in increased expression of the Wnt
signal inhibitor Dickkopf-1 (Dkk1; Dun et al., 2012). Both models
are in agreement with a neuroprotective role for Wnt signaling,
since treatment with Dkk1 exacerbated toxic effects, whilst GSK3
inhibition was found to be protective (L’Episcopo et al., 2011;
Dun et al., 2012). An unbiased genome-wide RNAseq approach
in mice treated with a variety of pesticides showed altered expres-
sion of mRNAs encoding Wnt signaling components in ventral
mid-brain and striatum (Gollamudi et al., 2012). Exposure to pes-
ticides is a well-known environment risk factor for Parkinson’s
disease, further suggesting that dysregulated Wnt signaling might
be a common mechanism underlying dopaminergic cell death in
Parkinson’s disease. Expression studies in human Parkinson’s dis-
ease brains have not been as conclusive, although it is important
to note that altered expression of Wnt pathway genes has been
reported in women but not in men (Cantuti-Castelvetri et al.,
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2007). These studies need to take into account that the brains ana-
lyzed are usually from individuals with symptomatic Parkinson’s
disease reﬂecting the loss of the majority of dopaminergic neu-
rons in the substantia nigra. Therefore, gene expression changes
are likely no longer reﬂective of the initial underlying etiology.
However, in addition to work on LRRK2 outlined above, other
clues from genetic causes of Parkinson’s disease are consistent with
altered Wnt signaling. Most notably Parkin, the product of the
PARK2 gene, has been reported to inhibit canonical Wnt signaling
(Rawal et al., 2009), whilst the transcription factor Nurr1, which
has been strongly linked to Parkinson’s disease, is regulated by
β-catenin (Jankovic et al., 2005; Kitagawa et al., 2007). Finally, it
is not just Parkinson’s disease-related genes that have been asso-
ciated with Wnt signaling; Wnt signaling genes themselves have
been linked to risk of Parkinson’s disease. In particular, GSK3β
has been suggested to modify disease risk in two studies (Kwok
et al., 2005; Kalinderi et al., 2011) although a third failed to ﬁnd
any affect (Wider et al., 2011).
In summary, therefore, LRRK2 binds three central Wnt sig-
naling components (Sancho et al., 2009; Lin et al., 2010; Berwick
and Harvey, 2012a), while loss of LRRK2 and pathogenic PARK8
mutations impact upon the activity of the canonical Wnt pathway
(Berwick and Harvey, 2012a). In addition, connections between
LRRK2 andWnt cascades are strengthened by a number of studies
supporting a role for dysregulated Wnt signaling in the early stage
of Parkinson’s disease. As outlined above, there is overwhelm-
ing evidence for a central function for LRRK2 in neurogenesis.
Combining these ideas, we postulate a speciﬁc role for LRRK2 in
Wnt-mediated neurogenesis. In the ﬁnal section of this article, we
will elaborate on this and suggest experimental approaches to test
our hypothesis.
LRRK2 AS A MAJOR PLAYER IN Wnt-MEDIATED NEURONAL
DIFFERENTIATION?
It is beyonddispute thatWnt ligands represent potentmorphogens
required for numerous aspects of neurogenesis, in particular the
development of dopaminergic neurons of the ventral mid-brain
(Brault et al., 2001; Castelo-Branco et al., 2010, 2004, 2003, 2010;
Parish et al., 2008; Carpenter et al., 2010). Degeneration of these
neurons underlies the typical motor symptoms associated with
Parkinson’s disease (Berwick and Harvey, 2012b). In this context,
deregulated Wnt signaling caused by PARK8 mutations might
cause subtle defects in establishing neuronal circuitries, leaving
these dopaminergic neurons more vulnerable to additional insults
important for the pathogenesis of Parkinson’s disease. In the
remainder of this review, we describe roles for Wnt signaling
pathways in modulating the same neurogenic events that were
reported to be inﬂuenced by LRRK2. Combined with evidence
of a function for LRRK2 as a Wnt signaling scaffold, this further
supports the idea that LRRK2 is a central player in Wnt-mediated
neurogenesis.
Evidence that Wnt ligands are major regulators of synap-
tic vesicle trafﬁcking and synaptogenesis is accumulating (Farías
et al., 2010; Inestrosa and Arenas, 2010). Published data support
pre-synaptic and post-synaptic effects of multiple branches of
Wnt signaling. Mammalian pre-synaptic development appears
particularly dependent on Wnt-7a, an agonist of the canonical
Wnt pathway (Farías et al., 2010). This Wnt ligand appears to be
required for normal expression of the pre-synaptic vesicle pro-
tein, synapsin 1, in the developing mouse brain (Hall et al., 2000),
with similar effects seen in mature neurons (Farías et al., 2007).
Treatment of cultured neurons with Dkk1, an LRP5/6 antago-
nist, has conﬁrmed this pre-synaptic effect of Wnt7a is through
the canonical pathway (Davis et al., 2008). Curiously though, data
from a number of laboratories suggest this effect is independent
of transcription (Farías et al., 2010). This observation has led to
the cascade by which Wnt7a modulates pre-synaptic and axonal
(see below) function being described as a “divergent” canonical
cascade (Ciani et al., 2004). Interestingly, LRRK2 is not just a key
Wnt signaling protein interacting with LRP6 but was also found to
interact with synapsin 1 and play a role in synaptic vesicle trafﬁck-
ing (Piccoli et al., 2011). The above evidence supports the idea of a
Wnt7a-induced LRRK2-mediated canonical Wnt pathway with a
direct transcriptionally independent effect on synapse formation
and maintenance.
Both LRRK2 and Parkinson’s disease pathogenesis have been
linked tomacroautophagy. Importantly, there is also evidence con-
sistentwith the idea thatmacroautophagy ismodulatedbyWnt lig-
ands. Strikingly, knock-down of β-catenin alone appears sufﬁcient
to induce macroautophagy in carcinoma cells (Chang et al., 2013).
Correspondingly, acute treatment of hippocampal neurons with
the β-catenin agonist 2-amino-4-[3,4-(methylenedioxy)benzyl-
amino]-6-(3-methoxyphenyl)pyrimidine (Liu et al., 2005) was
found to reduce oxygen–glucose deprivation-induced macroau-
tophagy (Wang et al., 2012). Taken together, these observations
suggest β-catenin to be a negative regulator of macroautophagy. In
addition, GSK3 activity almost certainly impacts upon macroau-
tophagy. GSK3has recently been reported to phosphorylate TIP60,
a histone acetyl transferase required for induction of macroau-
tophagy. Mutation of the reported phosphorylation site to an
alanine residue is sufﬁcient to prevent growth factor deprivation-
inducedmacroautophagy (Lin et al., 2012). In agreementwith this,
intranasal treatment with a GSK3 inhibitor peptide was reported
to result in decreased autophagy and increased lysosomal acidi-
ﬁcation in brains from an Alzheimer’s disease transgenic mouse
model (Avrahami et al., 2013), with similar results obtained in
vitro. These data predict a model where canonical Wnt pathway
activation – resulting in GSK3 inhibition and β-catenin accu-
mulation – would lead to decreased macroautophagy. However,
the events do not appear straightforward, since GSK3 inhibi-
tion in a neuroblastoma cell line has been reported to induce
increased lysosomal biogenesis, leading to increased macroau-
tophagic ﬂux (Parr et al., 2012). There are numerous reasons for
this potential discrepancy, for example, cell lines and treatments
used, however it is perhaps more relevant to observe that these
studies are at very early stages. More pertinently still, none look
at the regulation of macroautophagy during neural differentia-
tion, where one would expect the requirements placed on the
autophagic machinery of developing neurons to be more subtle
than under conditions of stress. In conclusion, even though evi-
dence supports the importance for LRRK2 and canonical Wnt
signaling in macroautophagy, the speciﬁc signal transduction cas-
cade, especially during neuronal differentiation, requires further
investigation.
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Wnt signaling is well-known to inﬂuence the dynamic insta-
bility of the microtubule cytoskeleton (Salinas, 2007). Multiple
proteins involved in both the canonical and non-canonical Wnt
pathway have been reported to affect microtubule stability, whilst
GSK3 phosphorylates a variety of MAPs (Cole et al., 2004; Zhou
et al., 2004; Salinas, 2007; Kim et al., 2011). Modulation of micro-
tubule structures by Wnt pathways appear common to multiple
cell types, for example Wnt ligands appear to be key regula-
tors of mitotic spindles (Walston et al., 2004). In light of the
above-described pre-synaptic function of LRRK2 and Wnt7a, it
is important to emphasize that a large number of studies show-
ing Wnt-mediated regulation of microtubules have used axon
outgrowth as the model system. Much of this work was initi-
ated by the observation that Wnt7a elicits axonal spreading and
branching in cultured cerebellar granule cells (Lucas and Sali-
nas, 1997), with corroborating data soon obtained in vivo (Hall
et al., 2000). This effect is mimicked by GSK3 inhibitors and
likely involves inhibition of phosphorylation of the microtubule-
associated protein MAP1B (Lucas and Salinas, 1997; Lucas et al.,
1998). Additional mechanisms involved in Wnt-mediated control
of axonal microtubules include the identiﬁcation of the β-catenin
destruction complex members APC and AXIN1 as microtubule
binding proteins in axons (Ciani et al., 2004; Purro et al., 2008).
The precise details are still being elucidated, but it is fair to
assume that, via interaction with microtubules, APC and AXIN1
create a spatially controlled signalingmechanism, speciﬁc to grow-
ing axons and growth cones. Importantly, LRRK2 also interacts
with microtubules, induces hyperphosphorylation of the axonal
MAP tau (Biskup et al., 2006; Gloeckner et al., 2006; Gandhi et al.,
2008; Gillardon, 2009a,b; Sancho et al., 2009; Dzamko et al., 2010;
Kawakami et al., 2012; Kett et al., 2012; Sheng et al., 2012), inter-
acts with components of the β-catenin destruction complex (Lin
et al., 2010; Berwick and Harvey, 2012a) and co-localizes with
DVL1 to neurites in cell culture models at early stages of dif-
ferentiation (Sancho et al., 2009). This further supports the idea
of a LRRK2 mediated Wnt signaling pathway important during
neuronal differentiation.
Above we have established good evidence for roles of LRRK2
and Wnt signaling in the regulation of pre-synaptic vesicle traf-
ﬁcking and microtubule dynamics, processes crucial for axonal
outgrowth and synaptogenesis. While the evidence of a role for
LRRK2 in macroautophagy is overwhelming, data supporting a
role forWnt signaling inmodulating this process aremore circum-
stantial. Nonetheless, the hypothesis that LRRK2 might function
speciﬁcally in Wnt-mediated neuritogenesis is plausible, espe-
cially for the latter stages of neurogenesis. But what about the
earlier stages? Here, the role for Wnt signaling is beyond doubt.
For example, treatment with Wnt1, which activates the canonical
Wnt pathway, causes expansion of ventral mid-brain precursors
(Castelo-Branco et al., 2003). Conversely, loss of Wnt1 in mice
leads to a complete failure of mid- and hind-brain precursors to
expand, leading to a near absence of these brain regions (Thomas
and Capecchi, 1990). Similarly, Wnt3a (another canonical path-
way agonist) secreted by hippocampal astrocytes has been shown
to be essential for adult neurogenesis in the dentate gyrus (Lie
et al., 2005). By contrast evidence of a function for LRRK2 in the
proliferation of neural precursors and in adult neurogenesis are
promising but at an early stage (Milosevic et al., 2009; Winner
et al., 2011).
In conclusion, there is a remarkable degree of overlap between
the effects of Wnt signaling and LRRK2 on neurogenesis. The
importance of LRRK2 in canonical Wnt signaling further sup-
ports the notion of a speciﬁc function for LRRK2 inWnt-mediated
neurogenesis. This hypothesis can be investigated by crossing the
relevant transgenic animals with known defects in Wnt-mediated
neuronal differentiation with LRRK2 transgenics looking for an
enhancement or rescue of phenotype. Of course, such exper-
iments come with the usual important caveats associated with
using animal models. For example, long non-coding RNAs are
known to be poorly conserved between species making their study
in model organisms of questionable relevance to humans (Pang
et al., 2006). Human-speciﬁc transcriptional networks have also
been reported in the brain (Konopka et al., 2012). However, at
the level of protein function, conservation across species is usu-
ally very high, and thus, even though the data should be treated
with caution, crossing of transgenic animal models is a justi-
ﬁable approach. Indeed, this strategy has proven particularly
useful for unveiling milder neurodevelopmental phenotypes. For
example, crossing of Wnt7a and Dvl1 knockout mice allowed
a requirement for these genes in the development of cerebel-
lar glomerular rosettes to be uncovered (Ahmad-Annuar et al.,
2006). As Lrrk2 knockout and familial PARK8 mutant transgenic
mice likely represent models of subtly increased and decreased
canonical Wnt signaling, respectively, crossing of these lines
with Wnt7a and/or Dvl1 knockout animals would be of great
interest.
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